stockrowFractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023.
- Revenue
- −57.1%
- EPS
- +71.9%
- Free cash flow
- +25.3%
- Total debt
- +1.54%
Quarter to June 2026, against a year earlier
Follow GUTS
Alert me
Fractyl Health, Inc. (GUTS) EV/Sales
As of 5 November 2026, Fractyl Health, Inc. (GUTS) trades at a EV/Sales of −51.6×. Over the past ten years it has ranged from −228× (February 2026) to 1,376× (June 2025); the current reading is higher than 7% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 563× | 38.92% |
| FY2023 | 405× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 563× | (18.47%) |
| Sep 2024 | 690× | (40.95%) |
| Jun 2024 | 1,169× | 34.80% |
| Mar 2024 | 868× | 114.07% |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GUTS Fractyl Health, Inc. | −51.6× |
| AEON AEON Biopharma, Inc. compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | n/m |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | 1.8× |
| BOLT Bolt Biotherapeutics, Inc. compare | 2.5× |
| DARE Dare Bioscience, Inc. compare | 3.6× |
| HIND Vyome Holdings, Inc. compare | 125× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)